At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...
Zacks.com on MSN3h
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance DisappointsBiogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...
The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...
Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...
As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...
Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (" Hyperscale Data ” or the " Company ”), today announced that it has successfully paid 32 consecutive monthly cash dividends ...
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback